Mission Bio, AGBL Group Partner on Tapestri Platform for CGTs

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, has signed an agreement with Alliance Global (AGBL Group), distributors of biomedical technology and products. The agreement will allow Mission Bio to expand its product offerings into the Middle East and Africa, two key regions for Mission Bio's growth strategy as it expands a global reach.
The partnership builds on Mission Bio's goal to provide high-quality single-cell multi-omics with the Tapestri platform globally, recently demonstrated through a strategic partnership with Sequanta Technologies Co., Ltd. to provide services to cell and gene therapy companies in mainland China.
Darrin Crisitello, Chief Commercial Officer of Mission Bio, said, "AGBL has a history of bringing new and innovative technologies to Middle East and African countries -- as evidenced by their previous success in commercializing hundreds of next-generation sequencers, and supporting all the national population genetics projects in the region. We look forward to working with their teams to bring the Tapestri platform to users throughout the region, helping meet demand for single-cell analysis and innovation."
"Mission Bio's Tapestri single-cell sequencing platform is an important addition to AGBL's portfolio of genomics products, and we are very excited about the possibilities the Tapestri platform shall give our customers in developing applications for both DNA and protein research on a single cell level," said Tamer Degheidy, MD, CEO and co-founder of AGBL. "Access to multi-omic, single-cell sequencing technology is key to the continued enablement of our research and clinical customers across our geographies. We are very excited about developing the use of the Tapestri platform in our clinical laboratories."